Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

Completed · Phase 1

Conditions studied: Diabetic Macular Edema

In brief

Evaluation of safety and tolerability of a single injection of NOVA63035 "Corticosteroid" administered at one of four doses in patients with diabetic macular edema (DME) secondary to diabetic retinopathy

Key facts

Study ID

NCT00665106

Run by

Santen SAS

People needed

20

Starts

2008-04-01

Expected to finish

2011-09-01

Last updated by the study team

2015-05-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• M \& F 18 years and older
• Diagnosed with diabetes mellitus and presenting diabetic retinopathy

You may not qualify if…

• Monocular
• History of current ocular hypertension or glaucoma in either eye defined
• Any significant ocular disease (other than diabetic retinopathy)

Where it is running

• Midwest Eye Institute — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.